BridgeBio is significantly advanced this course of an new therapy for amyloid heart disease, leveraging the investigational drug. Initial trial information reveals promising outcomes for those affected from a serious disease. The emphasis represents the company’s dedication to addressing unmet patient requirements in this cardiology field. … Read More